HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 10, October 2018 – Next-generation biosensors - Transforming the delivery of healthcare       » China tops world in alcohol-related deaths       » First China-developed drug for colorectal cancer approved in China       » World's first shrimp genome may reveal why females are superior       » Tetris-like program could speed breast cancer detection       » Wearable patch to monitor blood pressure inside body      
BIOBOARD - OCEANIA
Researcher looks to next generation antibody treatment for chronic kidney disease
A national medical grant has been awarded to fund research into the use of a next generation antibody therapy to treat chronic kidney disease.

Professor Carol Pollock from the University of Sydney has been awarded $768,000 from the National Health and Medical Research Council (NHMRC) to evaluate the drug, AD-114, being developed by the Australian biotech AdAlta.

The project grant, titled “A novel and unique protein i-body for the treatment of Chronic Kidney Disease through targeting CXCR4” will begin on 1 January 2018 and run for four years.

The grant will provide non-dilutive funding to build on the initial work completed by the Kolling Institute and University of Sydney that demonstrated the anti-fibrotic effects of AD-114 in the kidney via a different mechanism of action from currently-approved therapies.

AD-114 has the potential to provide a novel treatment for chronic kidney disease, which currently affects an estimated 1.7 million Australians.

AD-114 differs from existing treatment options and others currently in clinical development as it binds to the chemokine receptor CXCR4. The target CXCR4 is expressed at low levels or absent in healthy tissue and is increased and at high levels in tissue affected by a number of disease states, including fibrosis. AD-114 is the only anti-CXCR4 drug candidate being developed for the treatment of fibrosis.

AdAlta’s CEO, Sam Cobb said: “The research collaboration with the Kolling Institute and University of Sydney has provided the opportunity to expand the AD-114 pre-clinical package; demonstrating anti-fibrotic effects across a range of fibrotic diseases, which will be important to potential pharmaceutical partners.

We are looking forward to further developing AD-114 for Chronic Kidney Disease, providing an additional clinical application which further enhances the value of AD-114.”

Professor Carol Pollock added, “An increase in diabetes and obesity across the world is leading to a massive surge in the number of people diagnosed with CKD. The medical community is looking for alternate treatment options to treat CKD, highlighting the importance of research funding to evaluate new clinical targets. We are excited by the opportunity to further evaluate CXCR4’s involvement and this novel i-body for the treatment of Chronic Kidney Disease”.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy